pSivida Corp. (PSDV)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.17-0.05 (-1.55%)
At close: 4:00 PM EDT
People also watch:
ALIMPRANOPXAPGNXBDSI
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open3.19
Prev Close3.22
Bid0.00 x
Ask3.88 x 800
Day's Range3.11 - 3.19
52wk Range2.37 - 5.81
1y Target EstN/A
Market Cap108.34M
P/E Ratio (ttm)-4.65
Beta1.23
Volume38,531
Avg Vol (3m)74,071
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    pSivida to Present at the Ladenburg Thalmann Annual Healthcare Conference

    WATERTOWN, Mass., Sept. 22, 2016-- pSivida Corp., a leader in the development of sustained release drug delivery products primarily for eye diseases, announced today that Nancy Lurker, the Company’ s newly-appointed ...

  • GlobeNewswire7 days ago

    pSivida Reports Inducement Awards to New President and Chief Executive Officer

    WATERTOWN, Mass., Sept. 20, 2016-- pSivida Corp., a leader in the development of sustained release drug delivery products primarily for eye diseases, today reported the grant of inducement awards to its ...

  • American City Business Journals12 days ago

    Watertown's pSivida appoints new CEO to focus on commercialization

    Two days after posting dramatic annual losses, Watertown biotech pSivida Corp. has announced CEO Paul Ashton has resigned. The company (PSDV), known for its extended-release drug-and-device combination treatments for diseases that affect the back of the eye, said in a statement Ashton resigned to “pursue other interests." Nancy Lurker, who most recently served as president and CEO of healthcare commercialization company PDI Inc., has been named as president and CEO. Lurker said the executive change had little to do with the losses, but was more about moving the company from R&D to commercialization.